Announcement PDF Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Robert Romeo Proulx Date of last notice 13 December 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Date of change 10 July 2025 Note: Provide details of the circumstances giving rise to the relevant interest. + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Class 1. 1,404,082 Ordinary Shares 2. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2022, expiring 1 May 2026. 3. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2022, expiring 1 May 2027. 4. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2023, expiring 1 May 2028. 5. 2,000,000 Unlisted Performance Rights, expiring 22 August 2028, comprising of: (a) 600,000 Class A (Share price of at least $0.10 over 20 consecutive trading days); (b) 600,000 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 800, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 6. 625,000 Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. Unlisted Options Number acquired 2,000,000 Unlisted Options Number disposed N/A Value/Consideration Nil No. of securities held prior to change Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change 1. 1,404,082 Ordinary Shares 2. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2022, expiring 1 May 2026. 3. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2022, expiring 1 May 2027. 4. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2023, expiring 1 May 2028. 5. 2,000,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 600,000 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 600,000 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); (c) 800, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 6. 625,000 Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. 7. 2,000,000 Unlisted Options, exercisable at $0.012 (1.2 cents), expiring 29 May 2030, comprising of: (a) 400,000 Options vesting on submission of MagSense@ HER2 IND for Phase 2 study (or equivalent regulatory submission for another jurisdiction); (b) 400,000 Options vesting on first patient dosed in a Phase 2 study; (c) 1,000,000 Options vesting on completion of a Phase 2 study; and (d) 200,000 Options vesting on submission of an IND (or like regulatory approval) for a second imaging agent. Nature of change Issue of Unlisted Options which were approved by Shareholders at the Company’s Annual General Meeting held on 30 May 2025. Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. Appendix 3Y Page 4 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Brett Mitchell Date of last notice 13 December 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) 1. Mr Brett Mitchell and Mrs Michelle Mitchell <Lefthanders Super Fund A/C> (Trustee and Beneficiary) Note: Provide details of the circumstances giving rise to the relevant interest. 2. Mr Brett Mitchell and Mrs Michelle Mitchell <Mitchell Spring Family A/C> (Trustee and Beneficiary) Date of change + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 10 July 2025 Appendix 3Y Change of Director’s Interest Notice Class 1. 4,270,908 Ordinary Shares 2. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 3. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). Unlisted Options Number acquired 2,000,000 Unlisted Options Number disposed N/A Value/Consideration Nil No. of securities held prior to change Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 1. 2. 4,270,908 Ordinary Shares 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 3. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 4. 2,000,000 Unlisted Options, exercisable at $0.019 (1.9 cents), expiring 29 May 2028, comprising of: (a) 666,667 Options vesting on the issue date; (b) 666,667 Options vesting one year from the issue date; and (c) 666,666 Options vesting on the second anniversary of the issue date. Issue of Unlisted Options which were approved by Shareholders at the Company’s Annual General Meeting held on 30 May 2025. Appendix 3Y Change of Director’s Interest Notice Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. Appendix 3Y Page 4 01/01/2011